Chief Legal Officer · ENANTA PHARMACEUTICALS INC (ENTA)

Matthew Kowalsky

FY2024 is the first fiscal year CompBrief holds for Matthew Kowalsky as a named executive officer of ENANTA PHARMACEUTICALS; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2024

$1,473,260

Salary $195,342Stock awards $74,276

2nd of 5 named executive officers at Enanta Pharmaceuticals by FY2024 total.

5 named officers on file for ENANTA PHARMACEUTICALS, FY2024

Matthew Kowalsky’s pay file — $29

  • 1 fiscal year of pay, line by line
  • 2 equity grants, each cited to its filing
  • ENTA’s disclosed peer group of 21 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how ENANTA PHARMACEUTICALS’s whole pay program stands against its peers

  • ENANTA PHARMACEUTICALS’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on ENTA→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed January 27, 2025 (DEF 14A).

Free

Get Matthew Kowalsky’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Matthew Kowalsky compensation by year

ENANTA PHARMACEUTICALS Summary Compensation Table · the one fiscal year held
In US dollars, as ENANTA PHARMACEUTICALS reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2024
Salary$195,342
Bonus$0
Stock awards$74,276
Option awards$1,090,560
Non-equity incentive$111,780
Pension and deferred compensation$0
All other$1,302
Total$1,473,260

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: ENANTA PHARMACEUTICALS INC DEF 14A filed January 27, 2025, accession 0000950170-25-009168, and prior-year filings. Open the filing on EDGAR.

How this page was built: the ENANTA PHARMACEUTICALS INC filed document, accession 0000950170-25-009168. Every figure is read from that document and cited to the page and table it appears in. Filed January 27, 2025.

Equity holdings

unvested awards at FY2024 year-end
TypeUnvested unitsValue at year-endExercise price
PSU4,395$45,532—
PSU4,395$45,532—
Option150,000—$13.25

Per the Outstanding Equity Awards at Fiscal Year-End table in ENANTA PHARMACEUTICALS INC's FY2024 proxy; value at the fiscal year-end close, as the company printed it.

ENANTA PHARMACEUTICALS’s named executive officers, FY2024

as the company reported each
Named executive officerRoleFY2024 total
Jay LulyPresident and Chief Executive Officer$2,695,276
Matthew Kowalsky · this pageChief Legal Officer$1,473,260
Scott RottinghausChief Medical Officer$1,257,074
Yat Sun OrChief Scientific Officer$1,222,705
Paul MellettChief Financial and Administrative Officer$1,136,539

The full ENANTA PHARMACEUTICALS compensation record

free company brief

This page is one person within ENANTA PHARMACEUTICALS's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the ENANTA PHARMACEUTICALS proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are ENANTA PHARMACEUTICALS's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Matthew Kowalsky's compensation dossier · One-time report. No refunds.